ArticleJournal of bone metabolism2025
Alveolar Bone Mesenchymal Stem Cells Exhibit Osteogenic Potential with Fewer Macrophages.
Article in Journal of bone metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microenvironment-mediated stem cell fate in periodontal tissue remodeling and repair.Bioactive materials · 2026Review
- CaMKIV negatively regulates osteoblast differentiation by modulating c-Fos and NFATc1 signaling: an in vitro and in vivo mechanistic study.BMB reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundMesenchymal stem cells (MSCs) derived from various tissues demonstrate regenerative potential in bone tissue engineering. However, bone marrow-derived MSCs (BMSCs) often contain macrophage contamination, necessitating additional purification steps such as liposomal clodronate treatment. In contrast, alveolar bone MSCs alveolar bone-derived MSCs (aBMSCs) may offer a distinct advantage due to their lower macrophage contamination.
methodsThe aBMSCs were isolated from alveolar bone fragments through enzymatic digestion, and their macrophage contamination was compared to BMSCs using flow cytometry for MSC surface markers (CD44, CD105, CD90.2, CD140a) and macrophage markers (CD11b).
resultsThe aBMSCs exhibited significantly lower macrophage contamination compared to BMSCs and maintained osteogenic potential. Under inflammatory conditions in the presence of interleukin-1β (IL-1β), aBMSCs maintained their osteogenic capacity-unlike BMSCs, whose differentiation was impaired-accompanied by further activation of Protocadherin FAT4 (FAT4), which is known to initiate the osteogenic differentiation trajectory of aBMSCs.
conclusionsThese results highlight aBMSCs as a promising cell source for bone regeneration, offering low macrophage contamination and sustained osteogenic potential under inflammatory conditions such as IL-1β exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.